Compare CVS Health Corp (CVS) vs Sibanye Stillwater Ltd (SBSW) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
CVS Health Corp vs Sibanye Stillwater Ltd — how do they compare? CVS Health Corp trades at $86.25 (market cap $112.29B), while Sibanye Stillwater Ltd trades at $10.12 (market cap $6.88B). The key difference: CVS Health Corp is far larger — about 16.3× Sibanye Stillwater Ltd's market cap, and Sibanye Stillwater Ltd pays the higher dividend (8.17%). Which is the better fit depends on your goals — on Pluang, investors hold CVS Health Corp for 83 Days and Sibanye Stillwater Ltd for 51 Days on average.
| CVS | SBSW | |
|---|---|---|
Market Cap | $112.29B | $6.88B |
Volume | 7,763,676 | 4,474,536 |
Sector | Health | Basic Materials |
52-Week High | $110.60 | $21.12 |
52-Week Low | $70.08 | $8.00 |
Typical Hold Time | 83 Days | 51 Days |
Enterprise Value | $174.64B | $7.78B |
Dividend Yield | 3.03% | 8.17% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CVS Health trades at $87.95, up 1.76% with strong analyst support (85% buy ratings) and a $111.20 consensus price target suggesting 26% upside. Recent quarterly earnings consistently beat expectations, with Q2 2026 EPS of $2.58 surpassing the $1.85 estimate. Revenue growth remains solid at $402.07 billion for 2025, though net margins compressed to 1.18%. Technical indicators show a bullish overall signal with support at $87 and resistance at $89.
The outlook remains positive given CVS's dominant market position and Medicare expansion plans, but investors face risks from reimbursement pressures and ongoing legal investigations. Earnings growth and successful execution of healthcare services integration represent the primary catalysts for continued stock appreciation.
SBSW trades at $9.68, down 3.3% today, with a bearish technical outlook. The company shows mixed fundamentals with strong valuation ratios (P/E 7.98, P/S 0.69) but negative net income of -$5.17B in 2025. Recent Q2 2026 earnings beat expectations with EPS of $1.34 versus $1.26 forecast. Operating cash flow improved significantly to $21.41B in 2025, while analyst consensus is bullish with a $14.25 price target.
The outlook suggests potential upside based on valuation and analyst targets, but risks include persistent negative earnings, high debt levels, and commodity price volatility. Investor sentiment is cautiously optimistic following strong H1 2026 results and institutional buying activity.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About CVS Health Corp
Following its acquisition of Aetna in late 2018, CVS Health now provides an even more integrated healthcare-services offering for its members. Legacy CVS combined both the largest pharmacy benefit manager, processing over 2 billion adjusted claims annually, and a sizable pharmacy operation, including nearly 10,000 retail pharmacy locations primarily in the U.S. Adding a managed-care organization with 24 million medical members gives the company a strong position in the insurance industry and should help CVS better control overall healthcare costs for its clients.
Read more on CVS →About Sibanye Stillwater Ltd
Sibanye Stillwater Ltd is a South Africa-focused mining company. The Group currently owns and operates five underground and surface gold operations in South Africa: the Cooke, DRDGOLD, Driefontein, and Kloof operations in the West Witwatersrand region, and the Beatrix Operation in the southern Free State province. In addition to mining, the company owns and manages extraction and processing facilities at its operations, where gold-bearing ore is treated and beneficiated to produce gold dore. The gold dore is further refined at Rand Refinery into gold bars with a purity of at least 99.5% and is then sold on international markets. Sibanye holds a 44% interest in Rand Refinery, global refiners of gold, and the largest in Africa. Rand Refinery markets gold to customers around the world.
Read more on SBSW →
